$TVTX
Travere Therapeutics, Inc. Stock $tvtx

$tvtx Overview Financials Valuation SEC Filings Company Website

2017 Q4 Form 10-K Financial Statement

#000143853318000006 Filed on February 27, 2018

Income Statement

Concept	2017 Q4	2017 Q3	2017
Revenue	$42.00K	$40.00K	$154.9M
YoY Change	-99.89%	-99.88%	15.98%
Cost Of Revenue	$1.170M	$925.0K	$3.605M
YoY Change	-2.5%	-41.2%	-20.84%
Gross Profit	$41.00M	-$885.0K	$151.3M
YoY Change	13.51%	-102.73%	17.28%
Gross Profit Margin	97619.05%	-2212.5%	97.67%
Selling, General & Admin	$22.40M	$24.85M	$101.3M
YoY Change	-0.8%	5.91%	10.22%
% of Gross Profit	54.63%		66.96%
Research & Development	$19.49M	$19.61M	$78.17M
YoY Change	-2.55%	6.5%	10.37%
% of Gross Profit	47.54%		51.65%
Depreciation & Amortization	$4.460M	$4.620M	$17.80M
YoY Change	6.44%	12.96%	10.34%
% of Gross Profit	10.88%		11.76%
Operating Expenses	$57.35M	$50.95M	$208.7M
YoY Change	3.25%	-6.2%	8.82%
Operating Profit	-$15.18M	-$10.61M	-$53.79M
YoY Change	-16.71%	-47.93%	-7.6%
Interest Expense	-$4.230M	-$660.0K	$4.400M
YoY Change	227.91%	120.74%	-6.38%
% of Operating Profit
Other Income/Expense, Net	$4.139M	-$8.409M	-$4.572M
YoY Change	-169.74%	-181.85%	-823.42%
Pretax Income	-$11.04M	-$19.02M	-$58.36M
YoY Change	-10.17%	-37.95%	1.36%
Income Tax	$6.580M	-$1.223M	$1.368M
% Of Pretax Income
Net Earnings	-$17.62M	-$17.79M	-$59.73M
YoY Change	104.79%	-52.05%	24.69%
Net Earnings / Revenue	-41947.62%	-44485.0%	-38.55%
Basic Earnings Per Share	-$0.45	-$0.46	-$1.54
Diluted Earnings Per Share	-$0.55	-$0.46	-$1.54
COMMON SHARES
Basic Shares Outstanding	39.31M shares	38.65M shares	38.77M shares
Diluted Shares Outstanding		38.65M shares	38.77M shares

Balance Sheet

Concept	2017 Q4	2017 Q3	2017
SHORT-TERM ASSETS
Cash & Short-Term Investments	$222.7M	$303.9M	$300.6M
YoY Change	-12.98%	10.78%	17.47%
Cash & Equivalents	$99.39M	$98.99M	$99.40M
Short-Term Investments	$123.3M	$204.9M	$201.2M
Other Short-Term Assets	$6.000M	$2.600M	$6.000M
YoY Change	-27.71%	-27.78%	-27.71%
Inventory	$5.351M	$4.318M	$5.400M
Prepaid Expenses
Receivables	$13.87M	$14.54M	$13.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$325.8M	$325.3M	$325.8M
YoY Change	-1.97%	-5.04%	-1.99%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.230M	$2.717M	$3.200M
YoY Change	24.86%	611.26%	23.08%
Goodwill	$936.0K	$936.0K
YoY Change	0.0%	0.0%
Intangibles	$184.8M
YoY Change	1.52%
Long-Term Investments	$0.00
YoY Change
Other Assets	$5.556M	$7.101M	$5.600M
YoY Change	-24.55%	259.73%	-24.32%
Total Long-Term Assets	$194.5M	$195.2M	$194.5M
YoY Change	0.83%	2.81%	0.83%
TOTAL ASSETS
Total Short-Term Assets	$325.8M	$325.3M	$325.8M
Total Long-Term Assets	$194.5M	$195.2M	$194.5M
Total Assets	$520.3M	$520.5M	$520.3M
YoY Change	-0.94%	-2.24%	-0.95%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$18.94M	$7.370M	$18.90M
YoY Change	151.77%	140.38%	152.0%
Accrued Expenses	$36.02M	$32.25M	$24.00M
YoY Change	8.14%	-20.12%	2.13%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$85.67M	$83.90M	$85.70M
YoY Change	2.89%	-2.43%	2.88%
LONG-TERM LIABILITIES
Long-Term Debt	$45.10M	$44.90M	$45.10M
YoY Change	1.58%	1.35%	1.58%
Other Long-Term Liabilities	$2.472M	$3.808M	$96.50M
YoY Change	-38.35%	54.73%	15.71%
Total Long-Term Liabilities	$2.472M	$3.808M	$141.6M
YoY Change	-38.35%	54.73%	10.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$85.67M	$83.90M	$85.70M
Total Long-Term Liabilities	$2.472M	$3.808M	$141.6M
Total Liabilities	$227.2M	$216.0M	$227.2M
YoY Change	4.46%	-3.93%	4.46%
SHAREHOLDERS EQUITY
Retained Earnings	-$177.7M	-$160.0M
YoY Change	57.14%	53.21%
Common Stock	$471.8M	$465.2M
YoY Change	11.98%	12.8%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$293.1M	$304.5M	$293.1M
YoY Change
Total Liabilities & Shareholders Equity	$520.3M	$520.5M	$520.3M
YoY Change	-0.94%	-2.24%	-0.95%

Cashflow Statement

Concept	2017 Q4	2017 Q3	2017
OPERATING ACTIVITIES
Net Income	-$17.62M	-$17.79M	-$59.73M
YoY Change	104.79%	-52.05%	24.69%
Depreciation, Depletion And Amortization	$4.460M	$4.620M	$17.80M
YoY Change	6.44%	12.96%	10.34%
Cash From Operating Activities	-$860.0K	$6.200M	$7.403M
YoY Change	-89.87%	33.91%	-315.14%
INVESTING ACTIVITIES
Capital Expenditures	-$2.940M	-$3.740M	$887.0K
YoY Change	-30.5%	34.53%	-37.89%
Acquisitions			$0.00
YoY Change			-100.0%
Other Investing Activities	$2.840M	$1.540M	$59.61M
YoY Change	-91.82%	-147.09%	167.43%
Cash From Investing Activities	-$110.0K	-$2.180M	$45.60M
YoY Change	-100.36%	-63.97%	339.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change
Cash From Financing Activities	1.370M	5.830M	$5.445M
YoY Change	-127.13%	44.31%	-241.47%
NET CHANGE
Cash From Operating Activities	-860.0K	6.200M	$7.403M
Cash From Investing Activities	-110.0K	-2.180M	$45.60M
Cash From Financing Activities	1.370M	5.830M	$5.445M
Net Change In Cash	400.0K	9.850M	$58.39M
YoY Change	-97.64%	275.95%	1795.84%
FREE CASH FLOW
Cash From Operating Activities	-$860.0K	$6.200M	$7.403M
Capital Expenditures	-$2.940M	-$3.740M	$887.0K
Free Cash Flow	$2.080M	$9.940M	$6.516M
YoY Change	-148.83%	34.14%	-233.83%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2017	dei	Amendment Flag AmendmentFlag	false
CY2017	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2017	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2017	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
CY2017	dei	Document Period End Date DocumentPeriodEndDate	2017-12-31
CY2017	dei	Document Type DocumentType	10-K
CY2017	dei	Entity Central Index Key EntityCentralIndexKey	0001438533
CY2018Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39692923	shares
CY2017	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2017	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2017Q2	dei	Entity Public Float EntityPublicFloat	661868716	USD
CY2017	dei	Entity Registrant Name EntityRegistrantName	Retrophin, Inc.
CY2017	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2017	dei	Trading Symbol TradingSymbol	rtrx
CY2016Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	6967000	USD
CY2017Q4	rtrx	Accrued Government Rebate Reserves AccruedGovernmentRebateReserves	5883000	USD
CY2016Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1597000	USD
CY2017Q4	rtrx	Accrued Liabilities Miscellaneous AccruedLiabilitiesMiscellaneous	1523000	USD
CY2016Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	7311000	USD
CY2017Q4	rtrx	Accrued Liabilities Researchand Development Current AccruedLiabilitiesResearchandDevelopmentCurrent	6989000	USD
CY2016Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3333000	USD
CY2017Q4	rtrx	Accrued Liabilities Selling Generaland Administrative Current AccruedLiabilitiesSellingGeneralandAdministrativeCurrent	3896000	USD
CY2016Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	8068000	USD
CY2017Q4	rtrx	Accrued Royalties Noncurrent AccruedRoyaltiesNoncurrent	13095000	USD
CY2015	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	8219	USD
CY2016	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	11206000	USD
CY2017	rtrx	Accrued Royalty In Excess Of Minimum Payable To Sellers AccruedRoyaltyInExcessOfMinimumPayableToSellers	13247000	USD
CY2016Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	5766000	USD
CY2017Q4	rtrx	Accrued Royaltyand Contingent Consideration AccruedRoyaltyandContingentConsideration	6429000	USD
CY2016Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	16150000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration AcquisitionRelatedContingentConsideration	9100000	USD
CY2016Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	71328000	USD
CY2017Q4	rtrx	Acquisition Related Contingent Consideration Noncurrent AcquisitionRelatedContingentConsiderationNoncurrent	80900000	USD
CY2015	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	0	USD
CY2016	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	2025000	USD
CY2017	rtrx	Adjustment In Connection With Legal Fee Settlement Short Swing Profit Recovery AdjustmentInConnectionWithLegalFeeSettlementShortSwingProfitRecovery	0	USD
CY2015	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	0	USD
CY2016	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	0	USD
CY2017	rtrx	Amendment To Extend Term Of Agreement AmendmentToExtendTermOfAgreement	5885000	USD
CY2015	rtrx	Bargain Purchase Gain BargainPurchaseGain	49063000	USD
CY2016	rtrx	Bargain Purchase Gain BargainPurchaseGain	0	USD
CY2017	rtrx	Bargain Purchase Gain BargainPurchaseGain	0	USD
CY2015	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	1325000	USD
CY2016	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	4416000	USD
CY2017	rtrx	Business Combination Contingent Consideration Arrangements Changein Amountof Contingent Consideration Payment BusinessCombinationContingentConsiderationArrangementsChangeinAmountofContingentConsiderationPayment	3949000	USD
CY2015	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	0	USD
CY2016	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	-1655000	USD
CY2017	rtrx	Change In Fair Value Of Derivative Instruments ChangeInFairValueOfDerivativeInstruments	0	USD
CY2015	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2016	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2017	rtrx	Change In Fair Value Of Derivative Instruments In Shares ChangeInFairValueOfDerivativeInstrumentsInShares	0	shares
CY2015	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	0.1089
CY2016	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	-0.0110
CY2017	rtrx	Change In Fv Of Derivative Liability Warrants ChangeInFvOfDerivativeLiabilityWarrants	-0.0282
CY2017	rtrx	Common Stock Voting Rights Number Of Votes CommonStockVotingRightsNumberOfVotes	1
CY2017Q4	rtrx	Contractual Obligation Due In Rolling After Year Five ContractualObligationDueInRollingAfterYearFive	18277000	USD
CY2017Q4	rtrx	Contractual Obligation Due In Rolling Year Four And Five ContractualObligationDueInRollingYearFourAndFive	10879000	USD
CY2017Q4	rtrx	Contractual Obligation Due In Rolling Year Two And Three ContractualObligationDueInRollingYearTwoAndThree	57634000	USD
CY2017Q4	rtrx	Contractual Obligation Next Rolling Twelve Months ContractualObligationNextRollingTwelveMonths	13476000	USD
CY2015	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-15573000	USD
CY2016	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-22661000	USD
CY2017	rtrx	Deferred Income Tax Expense Benefit Netof Valuation Allowance DeferredIncomeTaxExpenseBenefitNetofValuationAllowance	-6425000	USD
CY2016Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	32792000	USD
CY2017Q4	rtrx	Deferred Tax Assets Contingent Consideration DeferredTaxAssetsContingentConsideration	23080000	USD
CY2016Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	9155000	USD
CY2017Q4	rtrx	Deferred Tax Assets Liabilities Net Before Valuation Allowance DeferredTaxAssetsLiabilitiesNetBeforeValuationAllowance	27624000	USD
CY2016Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	14547000	USD
CY2017Q4	rtrx	Deferred Tax Liabilities Deferred Gainon Installment Sale DeferredTaxLiabilitiesDeferredGainonInstallmentSale	0	USD
CY2016Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	0	USD
CY2017Q4	rtrx	Deferred Tax Liabilities Tax Basis Depreciation Lessthan Book Depreciation DeferredTaxLiabilitiesTaxBasisDepreciationLessthanBookDepreciation	0	USD
CY2015	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	1050000	USD
CY2016	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	0	USD
CY2017	rtrx	Derivative Financial Instruments Warrants Issued Recorded In Interest Expense DerivativeFinancialInstrumentsWarrantsIssuedRecordedInInterestExpense	0	USD
CY2015	rtrx	Early Payment Penalty EarlyPaymentPenalty	2250000	USD
CY2016	rtrx	Early Payment Penalty EarlyPaymentPenalty	0	USD
CY2017	rtrx	Early Payment Penalty EarlyPaymentPenalty	0	USD
CY2015	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	-0.1604
CY2016	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0.0000
CY2017	rtrx	Effective Income Tax Rate Reconciliation Non Taxable Bargain Purchase Gain EffectiveIncomeTaxRateReconciliationNonTaxableBargainPurchaseGain	0.0000
CY2015	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	28012000	USD
CY2016	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	20720000	USD
CY2017	rtrx	Exercise Of Warrants And Reclassification Of Derivative Liability ExerciseOfWarrantsAndReclassificationOfDerivativeLiability	14866000	USD
CY2015	rtrx	Finance Expense FinanceExpense	600000	USD
CY2016	rtrx	Finance Expense FinanceExpense	0	USD
CY2017	rtrx	Finance Expense FinanceExpense	0	USD
CY2015	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	140004000	USD
CY2016	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	0	USD
CY2017	rtrx	Gain Loss Upon Divestiture Of Assets GainLossUponDivestitureOfAssets	0	USD
CY2015	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	914000	USD
CY2016	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	0	USD
CY2017	rtrx	Gain Loss Upon Divestiture Of Assetsto Company GainLossUponDivestitureOfAssetstoCompany	0	USD
CY2015	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	0	USD
CY2016	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	-5212000	USD
CY2017	rtrx	Increase Decrease In Settlement Expense IncreaseDecreaseInSettlementExpense	-2625000	USD
CY2015	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	1267000	USD
CY2016	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	1927000	USD
CY2017	rtrx	Interest Receivablefrom Notes Receivable InterestReceivablefromNotesReceivable	651000	USD
CY2015	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
CY2016	rtrx	Legal Accrual Reversal LegalAccrualReversal	2967000	USD
CY2017	rtrx	Legal Accrual Reversal LegalAccrualReversal	0	USD
CY2017	rtrx	Legal Fee Judgment LegalFeeJudgment	2025000	USD
CY2017Q4	rtrx	Number Of Products Sold NumberOfProductsSold	3	product
CY2015	rtrx	Option Inducement Liability Reversaland Adjustments OptionInducementLiabilityReversalandAdjustments	3840000	USD
CY2015	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0079
CY2016	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0309
CY2017	rtrx	Other Federal Income Tax Expense OtherFederalIncomeTaxExpense	-0.0125
CY2015	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2016	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2017	rtrx	Payment Of Guaranteed Minimum Royalty PaymentOfGuaranteedMinimumRoyalty	2000000	USD
CY2015	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	0	USD
CY2016	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	115000	USD
CY2017	rtrx	Paymentsto Security Deposits PaymentstoSecurityDeposits	0	USD
CY2015	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	0	USD
CY2016	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13872000	USD
CY2015	rtrx	Releaseof Accrued Severance Amounts ReleaseofAccruedSeveranceAmounts	2126000	USD
CY2017	rtrx	Proceedsfrom Maturityof Note Receivable ProceedsfromMaturityofNoteReceivable	47500000	USD
CY2017Q4	rtrx	Purchase Obligation Duein Rolling Year Fourand Five PurchaseObligationDueinRollingYearFourandFive	1000000	USD
CY2017Q4	rtrx	Purchase Obligation Duein Rolling Year Twoand Three PurchaseObligationDueinRollingYearTwoandThree	1000000	USD
CY2017Q4	rtrx	Purchase Obligation Duein Rollingafter Year Five PurchaseObligationDueinRollingafterYearFive	500000	USD
CY2017Q4	rtrx	Purchase Obligation Next Rolling Twelve Months PurchaseObligationNextRollingTwelveMonths	5619000	USD
CY2014	rtrx	Reclassification Of Derivative Liabilities To Equity ReclassificationOfDerivativeLiabilitiesToEquity	2500000	USD
CY2015	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	25537000	USD
CY2016	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	14715000	USD
CY2017	rtrx	Reclassification Of Derivative Liability To Equity ReclassificationOfDerivativeLiabilityToEquity	11221000	USD
CY2015	rtrx	Shares Issued Related To Acquisition SharesIssuedRelatedToAcquisition	16000	USD
CY2016	rtrx	Shares Issued Related To Acquisition SharesIssuedRelatedToAcquisition	0	USD
CY2017	rtrx	Shares Issued Related To Acquisition SharesIssuedRelatedToAcquisition	0	USD
CY2017	rtrx	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Provisional Income Tax Expense TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateProvisionalIncomeTaxExpense	13000000	USD
CY2015Q1	rtrx	Underwriting Fees And Other Offering Costs UnderwritingFeesAndOtherOfferingCosts	9181991	USD
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	7522000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	18938000	USD
CY2016Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18510000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	33308000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	36018000	USD
CY2016Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2000000	USD
CY2016Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7441000	USD
CY2017Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	7749000	USD
CY2016Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	200000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	585000	USD
CY2016Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-490000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1015000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	421309000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	471800000	USD
CY2015	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	2461000	USD
CY2016	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1976000	USD
CY2017	us-gaap	Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	1723000	USD
CY2016	us-gaap	Adjustments To Additional Paid In Capital Income Tax Deficiency From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalIncomeTaxDeficiencyFromShareBasedCompensation	359000	USD
CY2015	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	2425000	USD
CY2015	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	25900000	USD
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	29102000	USD
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	26874000	USD
CY2016Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	300000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	200000	USD
CY2015	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	398000	USD
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1097000	USD
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1338000	USD
CY2015	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1340000	USD
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	656000	USD
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	656000	USD
CY2015	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	13231000	USD
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	15993000	USD
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	17331000	USD
CY2015	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3736992	shares
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9373686	shares
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11039901	shares
CY2016Q4	us-gaap	Assets Assets	525282000	USD
CY2017Q4	us-gaap	Assets Assets	520346000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	332352000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	325807000	USD
CY2016Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	214871000	USD
CY2017Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	201236000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2016Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	550000	USD
CY2017Q4	us-gaap	Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	726000	USD
CY2016Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	215414000	USD
CY2017Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	201962000	USD
CY2016Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	214871000	USD
CY2017Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	201236000	USD
CY2015	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	-300000	USD
CY2017	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	100000	USD
CY2015	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	13778000	USD
CY2016	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	18383000	USD
CY2017	us-gaap	Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1	19389000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	18204000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37805000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	41002000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99394000	USD
CY2015	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	19601000	USD
CY2016	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3197000	USD
CY2017	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	58392000	USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	37906669	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39373745	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	37906669	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39373745	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	4000	USD
CY2015	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	112270000	USD
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-47711000	USD
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-60256000	USD
CY2017Q4	us-gaap	Contractual Obligation ContractualObligation	100266000	USD
CY2016Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	44422000	USD
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	45077000	USD
CY2015	us-gaap	Cost Of Goods Sold CostOfGoodsSold	2185000	USD
CY2016	us-gaap	Cost Of Goods Sold CostOfGoodsSold	4554000	USD
CY2017	us-gaap	Cost Of Goods Sold CostOfGoodsSold	3605000	USD
CY2016Q4	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	-4868000	USD
CY2015	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	2094000	USD
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	13137000	USD
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6991000	USD
CY2015	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	3803000	USD
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	12982000	USD
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	7793000	USD
CY2015	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1709000	USD
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	-155000	USD
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	802000	USD
CY2015	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8296000	USD
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-18814000	USD
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-7965000	USD
CY2015	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-15573000	USD
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-22661000	USD
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6425000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	48700000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	16810000	USD
CY2016Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	6425000	USD
CY2017Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	0	USD
CY2015	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-7277000	USD
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-3847000	USD
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1540000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	57855000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	44434000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1832000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	1099000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	30000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	358000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	60000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1599000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	18520000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	15695000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	4621000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	2603000	USD
CY2016Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	15580000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27600000	USD
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27624000	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	6425000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	0	USD
CY2016Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	34153000	USD
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	16810000	USD
CY2015	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	USD
CY2016	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD
CY2017	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	USD
CY2015	us-gaap	Depreciation Depreciation	100000	USD
CY2016	us-gaap	Depreciation Depreciation	100000	USD
CY2017	us-gaap	Depreciation Depreciation	500000	USD
CY2015	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	13392000	USD
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16135000	USD
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17804000	USD
CY2016Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	22440000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	15710000	USD
CY2015	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	1881000	USD
CY2016	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2017	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
CY2015	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.49
CY2016Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.31
CY2016Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.37
CY2015	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-10000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.1630
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2162
CY2016Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.00
CY2016Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.29
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000
CY2016	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	117000	USD
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	0.0000
CY2017	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-58000	USD
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.46
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.54
CY2015	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.1100
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.1835
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.0245
CY2015	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.35
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.2702
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.34
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.46
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.45
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.54
CY2015	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.17
CY2016Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
CY2016Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.37
CY2016Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.00
CY2016Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.39
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.29
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.34
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost	-0.2329
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.1040
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0115
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.0348
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	0.0368
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0205
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Reconciling Items Percent EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent	-0.0104
CY2015	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0153
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0316
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.0330
CY2015	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	0.0785
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0158
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits EffectiveIncomeTaxRateReconciliationTaxCredits	-0.0579
CY2015	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	2425000	USD
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	-359000	USD
CY2017	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0	USD
CY2015	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	33307000	USD
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	USD
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1368000	USD
CY2015	us-gaap	Income Taxes Paid IncomeTaxesPaid	9610000	USD
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	7933000	USD
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	7172000	USD
CY2015	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	3379000	USD
CY2016	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	9672000	USD
CY2017	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	2656000	USD
CY2017Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-19000	USD
CY2017Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11000	USD
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-58363000	USD
CY2015	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-11770000	USD
CY2016Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-5070000	USD
CY2016Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-7392000	USD
CY2016Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6467000	USD
CY2016Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-3684000	USD
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-9679000	USD
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-2000	USD
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1000	USD
CY2016	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1655000	USD
CY2017	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4491000	USD
CY2016	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Fair Value Assumptions Expected Dividend Rate FairValueAssumptionsExpectedDividendRate	0
CY2016Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	33497000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	51046000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	74962000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	16871000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	16871000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	16871000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	16871000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	16871000	USD
CY2017Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	159317000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	0	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	1081000	USD
CY2015	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-40000	USD
CY2016	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	93000	USD
CY2017	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-339000	USD
CY2015	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	900000	USD
CY2015	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	15500000	USD
CY2016	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2017	us-gaap	Gain Loss Related To Litigation Settlement GainLossRelatedToLitigationSettlement	0	USD
CY2015	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-4151000	USD
CY2016	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2017	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2016Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2017Q4	us-gaap	Goodwill Goodwill	936000	USD
CY2015	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2016	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0	USD
CY2015	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	4700000	USD
CY2016	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	0	USD
CY2015	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	4710000	USD
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0	USD
CY2015	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	105467000	USD
CY2016Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	6146000	USD
CY2016Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-20795000	USD
CY2016Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-30646000	USD
CY2016Q4	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12287000	USD
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57582000	USD
CY2017Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-13000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-15000	USD
CY2015	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4504000	USD
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-37113000	USD
CY2016Q4	us-gaap	Net Income Loss NetIncomeLoss	-8603000	USD
CY2016Q4	us-gaap	Marketable Securities MarketableSecurities	214871000	USD
CY2017Q4	us-gaap	Marketable Securities MarketableSecurities	201236000	USD
CY2015	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	101602000	USD
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-3849000	USD
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5445000	USD
CY2015	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-80602000	USD
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10370000	USD
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	45602000	USD
CY2015	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1389000	USD
CY2017Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1916000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	2826000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	5351000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1336000	USD
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6090000	USD
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-4945000	USD
CY2015	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1174000	USD
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	306000	USD
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1706000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	966000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2447000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2702000	USD
CY2015	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	8107000	USD
CY2016	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-4644000	USD
CY2017	us-gaap	Increase Decrease In Prepaid Taxes IncreaseDecreaseInPrepaidTaxes	-621000	USD
CY2015	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	2642160	shares
CY2016	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2017	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
CY2016Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	215540000	USD
CY2017Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	235863000	USD
CY2016Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	182043000	USD
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	184817000	USD
CY2015	us-gaap	Interest Expense InterestExpense	7700000	USD
CY2016	us-gaap	Interest Expense InterestExpense	800000	USD
CY2017	us-gaap	Interest Expense InterestExpense	1200000	USD
CY2015	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7748000	USD
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-759000	USD
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1188000	USD
CY2015	us-gaap	Interest Paid InterestPaid	5838000	USD
CY2016	us-gaap	Interest Paid InterestPaid	2070000	USD
CY2017	us-gaap	Interest Paid InterestPaid	2070000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	1490000	USD
CY2017Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	3435000	USD
CY2016Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	600000	USD
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	700000	USD
CY2016Q4	us-gaap	Liabilities Liabilities	217515000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	227212000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	525282000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	520346000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	83262000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	85668000	USD
CY2015	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	0	USD
CY2016	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5212000	USD
CY2016	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	5200000	USD
CY2017	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	2625000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-47903000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-11000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-18000	USD
CY2017Q4	us-gaap	Net Income Loss NetIncomeLoss	-18000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3441000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-59731000	USD
CY2015	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	119118000	USD
CY2016	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-49558000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	7403000	USD
CY2015	us-gaap	Net Income Loss NetIncomeLoss	117237000	USD
CY2016Q1	us-gaap	Net Income Loss NetIncomeLoss	11216000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-13403000	USD
CY2017	us-gaap	Net Income Loss Attributable To Parent Diluted NetIncomeLossAttributableToParentDiluted	-59731000	USD
CY2015	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	156215000	USD
CY2016Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-14387000	USD
CY2016Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9416000	USD
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	10274000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-13000	USD
CY2016Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-5935000	USD
CY2016	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	632000	USD
CY2017Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
CY2017Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-8000	USD
CY2017Q4	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4000	USD
CY2017	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-4572000	USD
CY2016Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	46849000	USD
CY2017Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	0	USD
CY2017	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017	us-gaap	Number Of Reporting Units NumberOfReportingUnits	1	reporting_unit
CY2015	us-gaap	Operating Expenses OperatingExpenses	150640000	USD
CY2016Q1	us-gaap	Operating Expenses OperatingExpenses	37249000	USD
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	44690000	USD
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	54317000	USD
CY2016Q4	us-gaap	Operating Expenses OperatingExpenses	55549000	USD
CY2016	us-gaap	Operating Expenses OperatingExpenses	191805000	USD
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	48000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	52000	USD
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	51000	USD
CY2017Q4	us-gaap	Operating Expenses OperatingExpenses	57000	USD
CY2017	us-gaap	Operating Expenses OperatingExpenses	208728000	USD
CY2015	us-gaap	Operating Income Loss OperatingIncomeLoss	-50748000	USD
CY2016Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-8241000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11379000	USD
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-20372000	USD
CY2016Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-18222000	USD
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	-58214000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-14000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11000	USD
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	-15000	USD
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	-53791000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	16037000	USD
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	78168000	USD
CY2015	us-gaap	Restructuring Charges RestructuringCharges	0	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling After Year Five OperatingLeasesFutureMinimumPaymentsDueInRollingAfterYearFive	4222000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Four And Five OperatingLeasesFutureMinimumPaymentsDueInRollingYearFourAndFive	5046000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Due In Rolling Year Two And Three OperatingLeasesFutureMinimumPaymentsDueInRollingYearTwoAndThree	4757000	USD
CY2017Q4	us-gaap	Operating Leases Future Minimum Payments Next Rolling Twelve Months OperatingLeasesFutureMinimumPaymentsNextRollingTwelveMonths	2012000	USD
CY2016Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	7364000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	5556000	USD
CY2015	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-4927000	USD
CY2016	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	99000	USD
CY2017	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-186000	USD
CY2015	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-4927000	USD
CY2016	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	99000	USD
CY2017	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-186000	USD
CY2016Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	1842000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3902000	USD
CY2016Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4010000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	2472000	USD
CY2015	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-405000	USD
CY2016	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-54000	USD
CY2017	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-526000	USD
CY2015	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-296000	USD
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-264000	USD
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1107000	USD
CY2015	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	3103000	USD
CY2016	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	10511000	USD
CY2017	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	4099000	USD
CY2015	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	9500000	USD
CY2016	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2017	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	0	USD
CY2017	us-gaap	Payments For Restructuring PaymentsForRestructuring	897000	USD
CY2015	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	33430000	USD
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	500000	USD
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
CY2015	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	7008000	USD
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	10496000	USD
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13122000	USD
CY2015	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	198530000	USD
CY2016	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	184111000	USD
CY2017	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	102415000	USD
CY2015	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	22000	USD
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1428000	USD
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	887000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	8087000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2787000	USD
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4831000	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3112000	USD
CY2016Q4	us-gaap	Prepaid Taxes PrepaidTaxes	3463000	USD
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	2842000	USD
CY2015	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	149487000	USD
CY2016	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2017	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2015	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	4475000	USD
CY2016	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	6005000	USD
CY2017	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	3645000	USD
CY2015	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2016	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0	USD
CY2017	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	664000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	10000000	USD
CY2015	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	9977000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	159520000	USD
CY2016	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	159500000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	114526000	USD
CY2017	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	114500000	USD
CY2015	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	148411000	USD
CY2016	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2017	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
CY2015	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6818000	USD
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	4016000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3815000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2587000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3230000	USD
CY2015	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2016	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2017	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	200000	USD
CY2017Q4	us-gaap	Purchase Obligation PurchaseObligation	8119000	USD
CY2015	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	45000000	USD
CY2016	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2017	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	0	USD
CY2015	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	2000000	USD
CY2016	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	1000000	USD
CY2017	us-gaap	Repayments Of Other Debt RepaymentsOfOtherDebt	852000	USD
CY2015	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	50426000	USD
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70822000	USD
CY2016	us-gaap	Restructuring Charges RestructuringCharges	893000	USD
CY2017	us-gaap	Restructuring Charges RestructuringCharges	3608000	USD
CY2016	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	4016000	USD
CY2016Q4	us-gaap	Restructuring Reserve RestructuringReserve	893000	USD
CY2017Q4	us-gaap	Restructuring Reserve RestructuringReserve	3549000	USD
CY2017Q3	us-gaap	Restructuring Reserve Accrual Adjustment1 RestructuringReserveAccrualAdjustment1	-55000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-113056000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-177655000	USD
CY2015	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	99892000	USD
CY2016Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	29008000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33311000	USD
CY2017	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	8087000	USD
CY2016Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	33945000	USD
CY2016Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	37327000	USD
CY2016	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	133591000	USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	34000	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	39000	USD
CY2017Q3	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	40000	USD
CY2017Q4	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	42000	USD
CY2017	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	154937000	USD
CY2015	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	79541000	USD
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	91941000	USD
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	101333000	USD
CY2015	us-gaap	Share Based Compensation ShareBasedCompensation	25900000	USD
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	29102000	USD
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	26874000	USD
CY2016Q4	us-gaap	Share Price SharePrice	18.93
CY2017Q4	us-gaap	Share Price SharePrice	21.07
CY2015Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	19.00
CY2015	us-gaap	Stock Granted During Period Value Sharebased Compensation Gross StockGrantedDuringPeriodValueSharebasedCompensationGross	6818000	USD
CY2017	us-gaap	Stock Issued During Period Shares Employee Stock Purchase Plans StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans	40022	shares
CY2015	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	15844000	USD
CY2017	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	893000	USD
CY2015	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	139987000	USD
CY2015	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	25900000	USD
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	29102000	USD
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	26645000	USD
CY2015	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	3200000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-37251000	USD
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	299971000	USD
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	307767000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	293134000	USD
CY2015	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-40000	USD
CY2016	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	96000	USD
CY2017	us-gaap	Temporary Equity Foreign Currency Translation Adjustments TemporaryEquityForeignCurrencyTranslationAdjustments	-339000	USD
CY2015	us-gaap	Treasury Stock Retired Par Value Method Amount TreasuryStockRetiredParValueMethodAmount	0	USD
CY2015Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	3324000	USD
CY2016Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1500000	USD
CY2017Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1824000	USD
CY2017	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	1500000	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	0	USD
CY2016	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0	USD
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	12000000	USD
CY2015	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	37581439	shares
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38288012	shares
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	38769816	shares
CY2015	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	33560249	shares
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36997865	shares
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38769816	shares
CY2017	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;padding-top:12px;font-size:13pt;"><font style="font-family:Arial;font-size:13pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:16px;font-size:12pt;"><font style="font-family:Arial;font-size:12pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Organization and Description of Business</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Retrophin, Inc. (“we”, “our”, “us”, “Retrophin” and the “Company”) refers to Retrophin, Inc., a Delaware corporation, as well as our direct and indirect subsidiaries. Retrophin is a fully integrated biopharmaceutical company headquartered in San Diego, California focused on the development, acquisition and commercialization of therapies for the treatment of rare diseases. We regularly evaluate and, where appropriate, act on opportunities to expand our product pipeline through licenses and acquisitions of products in areas that will serve patients with rare diseases and that we believe offer attractive growth characteristics. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">The Company is developing the following pipeline products:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is developing fosmetpantotenate (RE-024), a novel small molecule, as a potential treatment for PKAN. PKAN is a genetic neurodegenerative disorder that is typically diagnosed in the first decade of life. Consequences of PKAN include dystonia, dysarthria, rigidity, retinal degeneration, and severe digestive problems. There are currently no viable treatment options for patients with PKAN. Fosmetpantotenate is a phosphopantothenate replacement therapy that aims to restore levels of this key substrate in PKAN patients. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Sparsentan (RE-021) is an investigational product candidate which acts as both a potent ARB, as well as a selective ERA, with in vitro selectivity toward endothelin receptor type A. The Company secured a license to sparsentan from Ligand Pharmaceuticals, Inc. and Bristol-Myers Squibb Company (who referred to it as DARA). The Company is developing sparsentan as a treatment for FSGS, which is a leading cause of end-stage renal disease and nephrotic syndrome (“NS”). There are no U.S. Food and Drug Administration (the "FDA") approved treatments for FSGS and off-label resources are limited to ACE/ARBs, steroids, and immunosuppressant agents, which are effective in only a subset of patients.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company recently announced the exploration of a second indication, IgAN, for sparsentan. IgAN is characterized by hematuria, proteinuria, and variable rates of progressive renal failure. There is no FDA approved treatment for IgAN. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company is a party to a joint development agreement with Censa Pharmaceuticals Inc., a privately held biotechnology company focused on developing therapies for orphan metabolic diseases, to evaluate sepiapterin ("CNSA-001") for the treatment of phenylketonuria (PKU). CNSA-001 is an orally bioavailable form of a natural precursor of tetrahydrobiopterin (BH4) with the potential to provide improved phenylalanine (Phe) reduction in patients with PKU when compared to BH4. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">PKU is a rare, genetic metabolic condition in which the body cannot breakdown Phe due to a missing or defective phenylalanine hydroxylase (PAH) enzyme. High Phe levels can lead to developmental and physical growth delay, executive function impairment, seizures, and microcephaly caused by toxic Phe accumulation in the brain. </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In September 2017, the Company entered a three-way Cooperative Research and Development Agreement ("CRADA") with the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) and patient advocacy foundation NGLY1.org to collaborate on research efforts aimed at the identification of potential small molecule therapeutics for NGLY1 deficiency.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">N-glycanase deficiency, or NGLY1 deficiency, is an extremely rare genetic disorder believed to be caused by a deficiency in an enzyme called N-glycanase-1, which is encoded by the gene NGLY1. The condition has been characterized by symptoms such as developmental delays, seizures, complex hyperkinetic movement disorders, diminished reflexes and an inability to produce tears. There are no approved therapeutic options for NGLY1 deficiency, and current therapeutic strategies are limited to symptom management.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Liquid ursodeoxycholic acid ("L-UDCA") is a liquid formulation of ursodeoxycholic acid being developed for the treatment of a rare liver disease called primary biliary cholangitis ("PBC"). The Company obtained the rights to L-UDCA during 2016 with the intention of making L-UDCA commercially available to the subset of PBC patients who have difficulty swallowing.</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:12px;font-size:10.5pt;"><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">The Company sells the following </font><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;">three</font><font style="font-family:Arial;font-size:10.5pt;color:#666666;font-style:italic;font-weight:bold;text-decoration:none;"> products:</font></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Chenodal (chenodiol tablets) is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has been the standard of care for </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">cerebrotendinous xanthomatosis ("</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">CTX") patients for more than three decades and the Company is currently pursuing adding this indication to the label.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Cholbam (cholic acid capsules) is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9.5pt;padding-left:24px;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">•</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Thiola (tiopronin tablets) is approved in the United States for the </font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.</font></div></td></tr></table></div>
CY2017	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Reclassifications</font><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;font-style:italic;"> </font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">Certain reclassifications have been made to the prior year financial statements in order to conform to the current year’s presentation.</font></div></div>
CY2017	us-gaap	Revenue Recognition Services Licensing Fees RevenueRecognitionServicesLicensingFees	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Patents</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:justify;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">The Company expenses external costs, such as filing fees and associated attorney fees, incurred to obtain issued patents and patent applications pending. The Company also expenses costs associated with maintaining and defending patents subsequent to their issuance in the period incurred.</font></div></div>
CY2017	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Arial Narrow;font-size:10pt;color:#006ebf;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-align:left;font-size:9.5pt;"><font style="font-family:Arial Narrow;font-size:9.5pt;color:#000000;">In preparing financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include revenue recognition, valuing equity securities in share-based payments, estimating expenses of contracted research organizations, estimating fair value of equity instruments recorded as derivative liabilities, estimating the fair value of net assets acquired in business combinations, estimating the useful lives of depreciable and amortizable assets, goodwill impairment, estimating the fair value of contingent consideration, estimating of valuation allowances and uncertain tax positions, and estimates associated with the assessment of impairment for long lived assets.</font></div></div>

Files In Submission

Name	View Source	Status
0001438533-18-000006-index-headers.html	Edgar Link	pending
0001438533-18-000006-index.html	Edgar Link	pending
0001438533-18-000006.txt	Edgar Link	pending
0001438533-18-000006-xbrl.zip	Edgar Link	pending
ex1020-1231201710k.htm	Edgar Link	pending
ex211-1231201710k.htm	Edgar Link	pending
ex231-1231201710k.htm	Edgar Link	pending
ex311-1231201710k.htm	Edgar Link	pending
ex312-1231201710k.htm	Edgar Link	pending
ex321-1231201710k.htm	Edgar Link	pending
ex322-1231201710k.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pipeline201710k219.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
rtrx-20171231.xml	Edgar Link	completed
rtrx-20171231.xsd	Edgar Link	pending
rtrx-20171231x10k.htm	Edgar Link	pending
rtrx-20171231_cal.xml	Edgar Link	unprocessable
rtrx-20171231_def.xml	Edgar Link	unprocessable
rtrx-20171231_lab.xml	Edgar Link	unprocessable
rtrx-20171231_pre.xml	Edgar Link	unprocessable
Show.js	Edgar Link	pending
stockpricechart123117.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TVTX
Travere Therapeutics, Inc. Stock $tvtx

2017 Q4 Form 10-K Financial Statement

#000143853318000006 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX Travere Therapeutics, Inc. Stock $tvtx

2017 Q4 Form 10-K Financial Statement

#000143853318000006 Filed on February 27, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TVTX
Travere Therapeutics, Inc. Stock $tvtx